Journal Scans
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
BRAF-1 Inhibitors Accelerate Growth of Cutaneous Non-Melanoma Tumors
F Su, A Viros, C Milagre, K Trunzer, R Marais, et al
20120019
2012 Jan 19
N Engl J Med
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
N Engl J Med. 2012 Jan 19;366(3):207-215, F Su, A Viros, C Milagre, K Trunzer, R Marais, et al
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Inhibitors of oncogenic mutations at the BRAF locus have improved tumor responses and survival in patients with metastatic melanoma. Treatment of metastatic melanoma with BRAF-1 inhibitors, such as vemurafenib and dabrafenib, has been associated with increased risk of development of non-melanoma skin cancers, such as squamous cell carcinomas and keratoacanthomas. Vemurafenib inhibits oncogenic MAPK signaling via inhibition of ERK phosphorylation (pERK) in BRAF V600E–mutant cells; however, it appears...
